stockportfolio.pro
Lantheus Holdings, Inc. (LNTH)
Healthcare · Drug Manufacturers - Specialty & Generic · NasdaqGM
Lantheus Holdings, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $301.85M | $331.38M | $343.37M | $347.34M | $339.41M | $425.21M | $935.06M | $1.30B | $1.53B | $1.54B |
| Gross profit | $137.78M | $162.13M | $174.88M | $174.81M | $138.76M | $187.69M | $581.70M | $709.54M | $988.29M | $941.95M |
| Net income | $0 | $123.39M | $40.52M | $31.67M | $-13.47M | $-71.28M | $28.07M | $326.66M | $312.44M | $233.56M |
| Net margin | 0.0% | 37.2% | 11.8% | 9.1% | -4.0% | -16.8% | 3.0% | 25.2% | 20.4% | 15.2% |
Source: Lantheus Holdings, Inc. SEC filings (10-K). 13 years of history available in the interactive view.
Explore 13 years of Lantheus Holdings, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track LNTH in your portfolio →
About Lantheus Holdings, Inc.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
Lantheus Holdings, Inc. — frequently asked questions
What is Lantheus Holdings, Inc.'s revenue?
Lantheus Holdings, Inc. (LNTH) reported revenue of $1.54B for fiscal year 2025, up 0.5% from the prior year, according to its SEC filings.
Is Lantheus Holdings, Inc. profitable?
Yes. LNTH earned net income of $233.56M in fiscal 2025, a net margin of 15.2%.
What is LNTH's P/E ratio?
Lantheus Holdings, Inc. trades at a price-to-earnings ratio of about 24.0 based on the latest data in our nightly-refreshed cache.
How fast is Lantheus Holdings, Inc. growing?
LNTH's revenue grew at roughly 35.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Lantheus Holdings, Inc.'s official SEC filings (10-K and 10-Q), covering 13 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.